ImageneBio Stock Forecast

Stock Price Forecast

The 2 analysts that cover ImageneBio stock have a consensus rating of "Hold" and an average price target of $16, which forecasts a 175.86% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $30.

Price Target: $16 (+175.86%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$2.00	$16	$30	$30
Change	-65.52%	+175.86%	+417.24%	+417.24%

* Price targets were last updated on Nov 25, 2025.

Analyst Ratings

The average analyst rating for ImageneBio stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25
Strong Buy	0	0	0
Buy	1	1	1
Hold	0	0	0
Sell	0	1	1
Strong Sell	0	0	0
Total	1	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Martin Fan Wedbush	Wedbush	Sell Initiates $2	Sell	Initiates	$2	-65.52%	Nov 25, 2025
David Risinger Leerink Partners	Leerink Partners	Buy Initiates $30	Buy	Initiates	$30	+417.24%	Oct 24, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

269.34K

from 3.50M

-92.30%

from 3.50M

Revenue Next Year

n/a

from 269.34K

EPS This Year

-5.65

from -0.12

EPS Next Year

-3.23

from -5.65

Fiscal Year	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	7.96M	3.50M	269.34K	-	-	-	-
Revenue Growth	-	-56.04%	-92.30%	-	-	-	-
EPS	-0.10	-0.12	-5.65	-3.23	-2.89	-4.20	-3.56
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	4	4	4	2	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026
High	840,000	n/a
Avg	269,337	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026
High	-76.0%	-
Avg	-92.3%	-
Low	-	-

EPS Forecast

EPS	2025	2026
High	-1.94	-2.12
Avg	-5.65	-3.23
Low	-9.15	-4.29

EPS Growth

EPS Growth	2025	2026
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.